Curcumin 3.0—Therapeutic and Diagnostic Potential in Cancer and Beyond.
- Resource Type
- Article
- Authors
- Bachmeier, Beatrice E.; Blaheta, Roman
- Source
- International Journal of Molecular Sciences. May2022, Vol. 23 Issue 10, p5398-5398. 4p.
- Subject
- *CURCUMIN
*MOLECULAR docking
*EPIDERMAL growth factor receptors
- Language
- ISSN
- 1661-6596
The researchers found that tumour growth and metastasis are reduced when prostate cancer cells are treated with low-dose Curcumin and subsequent irradiation with visible light. Additionally, the combination of Curcumin and visible light irradiation is a smart therapeutic application to overcome Curcumin's pharmacological limitations without introducing toxicity. Comparable data were obtained for EGFR: 15 out of 50 Curcumin compounds were bound to EGFR with free binding energies of <-10 kcal/mol, while the binding affinity of Curcumin itself was >-10 kcal/mol. This includes the encapsulation of Curcumin into nanoparticles, the application of Curcumin in combination with visible light or the development of Curcumin derivatives. [Extracted from the article]